[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wei Chen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100584743","a-real-world-study-about-pmn-100584743",false,"NCT06893328","A Real World Study About PMN","PMNTRWS: A Non-interventional Study on Treatment and Therapeutic Efficacy in Chinese Patients With Primary Membranous Nephropathy (PMNTRWS)\"","PMNTRWS","Inclusion Criteria:\n\n1\\. Diagnosed as primary membranous nephropathy (PMN) by renal biopsy; 2. Aged over 18 years; 3. An average 24-hour urine protein ≥ 3.5g twice a week after treatment with ACE inhibitors or ARBs for at least 3 months.\n\n\\-\n\nExclusion Criteria:\n\n1. With secondary membranous nephropathy (such as hepatitis B and C, systemic lupus erythematosus, drug therapy, malignant tumors and other secondary causes);\n2. Active infection, such as active hepatitis B or hepatitis C, tuberculosis (evidence of active tuberculosis infection within 1 year), or human immunodeficiency virus HIV infection (positive for anti-HIV antibodies), etc.\n3. A history of immunodeficiency, including other acquired or congenital immunodeficiency diseases, or organ transplantation.\n\n   \\-","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","2 Years","OBSERVATIONAL","The investigators designed a randomized, controlled, multicenter clinical study to compare the efficacy and safety of rituximab combined with hormones versus rituximab monotherapy in the treatment of primary membranous nephropathy. At the same time, the investigators conducted a real-world study on patients who did not meet the inclusion and exclusion criteria or were unwilling to enter the RCT cohort, to further observe the trial results in a broader population.",[26],"Primary Membranous Nephropathy",[28],"Real-world Study","RECRUITING","2025-08-18",{"date":32,"type":33},"2025-08-22","ACTUAL",{"date":35,"type":33},"2024-11-11",{"date":37,"type":21},"2027-11-11",{"name":39,"class":40},"Wei Chen","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":62,"locationsCount":41},"100600509","a-real-world-study-about-anemia-in-chronic-kidney-disease-in-chinadasheng-100600509","NCT07098416","A Real-World Study About Anemia in Chronic Kidney Disease in China（DASHENG）","An In-Depth Analysis of the Present Diagnostic and Therapeutic Landscape for Renal Anemia in China's Real-World Clinical Environment: A Multicenter Retrospective Cohort Investigation（DASHENG Study）","DASHENG","Inclusion Criteria: CKD patients will be defined as those meeting any of the following criteria during the observation period:\n\n1. diagnosis of CKD (e.g., \"%chronic kidney disease%\", \"%chronic nephropathy%\", \"%renal failure%\", \"%nephritis%\" for complete ICD-9\u002F10 code mapping\\*)\n2. record of hemodialysis (HD) or peritoneal dialysis (PD) (refer to Attachment 2 for dialysis identification algorithms)\n3. ≥2 eGFR measurements \\\u003C60 mL\u002Fmin\u002F1.73m² (calculated using CKD-EPI equation) with ≥3-month interval (excluding acute kidney injury)\n\nExclusion Criteria:\n\n1. Non-renal anemia due to trauma, traffic accidents, major hemorrhage, or other confirmed etiologies (e.g., acute hemorrhagic anemia, nutritional deficiency anemia, hemolytic anemia);\n2. Diagnosis of acute kidney disease (AKD) without chronic kidney disease (CKD) comorbidity;\n3. Incomplete critical data elements (including age, sex, or visit dates).",{"count":51,"type":21},20000,"Anemia affects the quality of life of CKD patients and increases the risk of CKD progression. we conducted a real-world study on patients with anemia in CKD to analyze the disease characteristics and treatment in Chinese patients with CKD-anemia.",[54],"Anemia in Chronic Kidney Disease","NOT_YET_RECRUITING","2025-07-31",{"date":58,"type":33},"2025-08-01",{"date":58,"type":21},{"date":61,"type":21},"2027-08-31",{"name":39,"class":40},""]